Welcome to the Oncomine Blog
-
RET Aberrations and EGFR Exon 20 Insertions Testing in the Complex NSCLC Biomarker Landscape
In his recent OncomineWorld webinar, Dr. Fernando López-Ríos, MD, PhD (Department of Pathology, 12 d... -
Collaborating Early to Advance Precision Medicine – A Look Inside Thermo Fisher’s CDx Program with Garret Hampton
Companion diagnostic (CDx) tests are powerful tools in precision medicine and help advance more wide... -
University of Munich Evaluates the Oncomine Comprehensive Plus Assay for HRD Detection
Our OncomineWorld event in 2021 brought thousands of professionals together from around the world to... -
Case Study: High-Quality, Cost-Effective Genomic Testing and Genetic Profiling using NGS
In a recent case study interview, pathologist Federico Jauk, head of the Sequencing Laboratory at th... -
UAB Study Evaluates the Oncomine Myeloid Research Assay GX on the Genexus System
Performance of the Oncomine Myeloid Research Assay GX Craig Mackinnon, MD, PhD, Director of Genomic ... -
Let’s Do It Ourselves - A global expert consensus is emerging: by retaining oncology biomarker testing in-house, healthcare management and patient care benefit significantly
Over the last decade, precision oncology therapies dependent on biomarker-based diagnostics have pro... -
A Comprehensive Answer for Cancer: Is Comprehensive Genomic Profiling Always the Right Approach?
What is comprehensive genomic profiling (CGP)? CGP is the simultaneous detection of all classes of g... -
Biomarker Tests for Precision Oncology: DIY or Pay-for-Service?
Cancer patient management of is increasingly driven by biomarker assays – but how should we manage t... -
What is Comprehensive Genomic Profiling & is it the Right Solution for You?
What is comprehensive genomic profiling? Comprehensive genomic profiling, or CGP, is the simultaneou...